Breaking News Instant updates and real-time market news.

BGNE

BeiGene

$123.76

-12.655 (-9.28%)

, CELG

Celgene

$81.17

14.52 (21.79%)

14:50
01/03/19
01/03
14:50
01/03/19
14:50

BeiGene should be up, not down, on Celgene takeover news, says Maxim

After Bristol-Myers Squibb (BMY) announced an agreement to acquire Celgene (CELG), Maxim analyst Jason McCarthy noted that BeiGene (BGNE) shares have been under pressure, which he attributes to questions around Celgene's partnership with the company for tislelizumab. Assuming the transaction closes, he sees two potential scenarios: either Bristol-Myers ends the partnership and BeiGene regains global rights to tislelizumab or Bristol maintains the partnership as it could potentially want a second PD1 in its checkpoint portfolio to target indications not addressed by Opdivo. He sees the first scenario, that Bristol ends the deal, as most likely, but in that case McCarthy argues that BeiGene would be positioned "to get an even better deal" than it got with Celgene as tislelizumab is now in ten ongoing pivotal trials, nine of which BeiGene is already running, and is closer to an approval or approvals. The analyst, who sees the negativity in the stock on today's news as a buying opportunity and believes BeiGene shares should be up, not down, keeps a Buy rating and $170 price target on the stock.

BGNE

BeiGene

$123.76

-12.655 (-9.28%)

CELG

Celgene

$81.17

14.52 (21.79%)

BMY

Bristol-Myers

$44.68

-7.34 (-14.11%)

  • 03

    Jan

  • 03

    Jan

  • 03

    Jan

  • 06

    Jan

  • 24

    Jan

  • 28

    Jan

  • 18

    May

  • 20

    May

BGNE BeiGene
$123.76

-12.655 (-9.28%)

12/02/18
PIPR
12/02/18
NO CHANGE
Target $200
PIPR
Overweight
Piper Jaffray bullish on BeiGene ahead of China launches next year
Ahead of ASH this weekend, Piper Jaffray analyst Tyler Van Buren hosted meetings with BeiGene management. The analyst notes that the discussions give him increased confidence in the company's ability to successfully commercialize zanubrutinib and tislelizumab. He reiterates an Overweight rating and $200 price target on the shares.
11/28/18
ADAM
11/28/18
NO CHANGE
Target $21
ADAM
Buy
Zymeworks partnership deal with BeiGene a positive, says Canaccord
Canaccord analyst Arlinda Lee views Zymeworks' (ZYME) partnership with BeiGene (BGNE) as a positive as it ties in the company with a commercial-stage pharma company that has experience and a foothold in the Asia-Pacific region, where gastric cancers are more prevalent. She continues to view Zymeworks' complementary suite of "plug and play" platform technologies, particularly in its bi specific antibody platform, as attractive. Lee reiterated her Buy rating and $21 price target on Zymeworks shares.
11/21/18
11/21/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. BeiGene (BGNE) initiated with an Overweight at JPMorgan. 2. Gamida Cell (GMDA) initiated with an Outperform at BMO Capital and Oppenheimer. 3. Marker Therapeutics (MRKR) initiated with a Buy at Nomura Instinet. 4. Arco Platform (ARCE) initiated with a Buy at UBS. 5. nVent Electric (NVT) initiated with a Hold at Vertical Research. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/21/18
JPMS
11/21/18
INITIATION
Target $174
JPMS
Overweight
BeiGene initiated with an Overweight at JPMorgan
JPMorgan analyst Leon Chik last initiated coverage of BeiGene with an Overweight rating and $174 price target. The company over the past eight years has built a "strong innovative pipeline" composed of eight clinical candidates, three of which are already in Phase 3 clinical trials, Chik tells investors in a research note. He points out BeiGene also has exclusive licenses from Celgene for the China market to generate near-term sales and gross profits.
CELG Celgene
$81.17

14.52 (21.79%)

01/03/19
ADAM
01/03/19
DOWNGRADE
Target $102
ADAM
Hold
Celgene downgraded to Hold from Buy at Canaccord
Canaccord analyst John Newman downgraded Celgene (CELG) to Hold from Buy and lowered his price target on the shares to $102 from $140, citing the company's agreement to be acquired by Bristol-Myers (BMY).
01/03/19
LEER
01/03/19
DOWNGRADE
Target $102
LEER
Market Perform
Celgene downgraded to Market Perform from Outperform at Leerink
Leerink analyst Geoffrey Porges downgraded Celgene (CELG) to Market Perform from Outperform after the company agreed to be acquired by Bristol-Myers (BMY), stating that "the best deal is sometimes the only deal." He lowered his price target on Celgene shares to $102 from $112.
01/03/19
BARD
01/03/19
NO CHANGE
Target $92
BARD
Neutral
Baird calls Bristol-Myers buyout a 'very good deal' for Celgene
While admitting he was surprised as anyone to the news, Baird analyst Brian Skorney views the buyout by Bristol-Myers Squibb (BMY) as a "very good deal" for Celgene (CELG). The deal's success hinges on the outcome of Revlimid patent litigation, but for Celgene shareholders today, "its a big win," Skorney tells investors in a research note titled "Mega Mergers Are Back?" All told, the deal could be worth over $95 per share for Celgene, the analyst points out. With a contingent value right of $9.00 due in 2021, the analyst thinks the probability adjusted net present value of the CVR is around $5 to $6 per share. Skorney has a Neutral rating on Celgene with a $92 price target.
01/03/19
PIPR
01/03/19
NO CHANGE
PIPR
Piper sees Alexion, Biogen as potential targets after Celgene buyout
Piper Jaffray analyst Christopher Raymond remains "bullish on biotech" in the wake the announced acquisition of Celgene (CELG) by Bristol-Myers Squibb (BMY) for $74B in cash and stock, representing a 54% premium from yesterday's close. In a research note titled "Bristol for CELG - In Retrospect, it Makes Perfect Sense," Raymond says the market is likely to ask "who's next?" Among large-caps, Alexion Pharmaceuticals (ALXN) and Biogen (BIIB) would seem to make sense as potential targets, as well as BioMarin (BMRN), Raymond writes. And while any smid cap could likely be seen as a take-out candidate, Aimmune Therapeutics (AIMT), Deciphera Pharmaceuticals (DCPH) and Rigel Pharmaceuticals (RIGL) "in particular could make sense to any strategic buyer," adds the analyst.
BMY Bristol-Myers
$44.68

-7.34 (-14.11%)

TODAY'S FREE FLY STORIES

TNAV

TeleNav

$4.92

0.07 (1.44%)

19:37
11/20/19
11/20
19:37
11/20/19
19:37
Hot Stocks
TeleNav CEO buys 150K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

CRSP

Crispr Therapeutics

$67.31

-1.15 (-1.68%)

19:29
11/20/19
11/20
19:29
11/20/19
19:29
Syndicate
Breaking Syndicate news story on Crispr Therapeutics »

Crispr Therapeutics 4.25M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 21

    Nov

PFGC

Performance Food Group

$44.66

-0.13 (-0.29%)

19:26
11/20/19
11/20
19:26
11/20/19
19:26
Syndicate
Performance Food Group upsized 10.1M share offering said to price at $44.25 »

Report from Bloomberg. …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

INVH

Invitation Homes

$30.05

0.13 (0.43%)

19:10
11/20/19
11/20
19:10
11/20/19
19:10
Periodicals
Breaking Periodicals news story on Invitation Homes »

Invitation Homes stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

KRTX

Karuna Therapeutics

$108.42

-15.58 (-12.56%)

19:03
11/20/19
11/20
19:03
11/20/19
19:03
Syndicate
Karuna Therapeutics 2.6M share Secondary priced at $96.00 »

The deal priced below the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

GOOG

Alphabet

$1,302.26

-12.45 (-0.95%)

, GOOGL

Alphabet Class A

$1,301.34

-11.25 (-0.86%)

18:58
11/20/19
11/20
18:58
11/20/19
18:58
Hot Stocks
Google to limit election ads audience targeting, will prohibit 'deep fakes' »

Alphabet's Google…

GOOG

Alphabet

$1,302.26

-12.45 (-0.95%)

GOOGL

Alphabet Class A

$1,301.34

-11.25 (-0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CAN

Canaan

$0.00

(0.00%)

18:56
11/20/19
11/20
18:56
11/20/19
18:56
Syndicate
Canaan 10M share IPO priced at $9.00 »

The deal priced at low…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

NUAN

Nuance

$16.60

0.11 (0.67%)

, CPRT

Copart

$84.69

-1.64 (-1.90%)

18:51
11/20/19
11/20
18:51
11/20/19
18:51
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Nuance…

NUAN

Nuance

$16.60

0.11 (0.67%)

CPRT

Copart

$84.69

-1.64 (-1.90%)

LB

L Brands

$16.00

-1.19 (-6.92%)

JACK

Jack in the Box

$84.89

-0.08 (-0.09%)

SONO

Sonos

$13.87

-0.635 (-4.38%)

NTGN

Neon Therapeutics

$1.44

-0.04 (-2.70%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

UBER

Uber

$28.02

0.99 (3.66%)

LZB

La-Z-Boy

$36.23

-0.265 (-0.73%)

CUB

Cubic

$73.63

0.8 (1.10%)

NTES

NetEase

$287.68

-1.09 (-0.38%)

OPTN

Optinose

$11.42

0.84 (7.94%)

MTEM

Molecular Templates

$8.28

0.19 (2.35%)

PYPL

PayPal

$104.09

-0.85 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 21

    Nov

  • 04

    Dec

  • 05

    Dec

  • 05

    Dec

  • 06

    Dec

  • 10

    Dec

  • 10

    Dec

  • 21

    Nov

  • 21

    Nov

WNC

Wabash

$15.05

-0.2 (-1.31%)

18:48
11/20/19
11/20
18:48
11/20/19
18:48
Initiation
Wabash initiated  »

Wabash initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALSN

Allison Transmission

$45.51

-0.56 (-1.22%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Allison Transmission initiated  »

Allison Transmission…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAV

Navistar

$30.97

-0.97 (-3.04%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Navistar initiated  »

Navistar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCAR

Paccar

$78.85

-0.59 (-0.74%)

18:47
11/20/19
11/20
18:47
11/20/19
18:47
Initiation
Paccar initiated  »

Paccar initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMI

Cummins

$180.59

-2.36 (-1.29%)

18:46
11/20/19
11/20
18:46
11/20/19
18:46
Initiation
Cummins initiated  »

Cummins initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

VMC

Vulcan Materials

$140.72

-0.485 (-0.34%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Vulcan Materials initiated  »

Vulcan Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUM

Summit Materials

$24.18

0.3 (1.26%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Summit Materials initiated  »

Summit Materials…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

MLM

Martin Marietta

$263.10

1.36 (0.52%)

18:45
11/20/19
11/20
18:45
11/20/19
18:45
Initiation
Martin Marietta initiated  »

Martin Marietta initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

THC

Tenet

$31.36

-0.38 (-1.20%)

18:33
11/20/19
11/20
18:33
11/20/19
18:33
Hot Stocks
Tenet General Counsel sells 65K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFPT

Proofpoint

$119.56

1.25 (1.06%)

18:23
11/20/19
11/20
18:23
11/20/19
18:23
Hot Stocks
Proofpoint's Salle sells 10,479 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

LVMUY

LVMH

$0.00

(0.00%)

, TIF

Tiffany

$123.32

-0.16 (-0.13%)

18:21
11/20/19
11/20
18:21
11/20/19
18:21
Periodicals
Tiffany gives LVMH access to its books after raised bid, Reuters says »

LVMH (LVMUY) has…

LVMUY

LVMH

$0.00

(0.00%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

CPRT

Copart

$84.69

-1.64 (-1.90%)

18:05
11/20/19
11/20
18:05
11/20/19
18:05
Earnings
Copart reports Q1 non-GAAP EPS 65c, consensus 59c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 06

    Dec

NTES

NetEase

$287.68

-1.09 (-0.38%)

18:04
11/20/19
11/20
18:04
11/20/19
18:04
Earnings
NetEase reports Q3 adjusted ADS $5.12, consensus $3.12 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

LVMUY

LVMH

$0.00

(0.00%)

, TIF

Tiffany

$123.32

-0.16 (-0.13%)

17:58
11/20/19
11/20
17:58
11/20/19
17:58
Periodicals
LVMH, Tiffany in deal talks after LVMH boosts bid, Bloomberg reports »

LVMH (LVMUY) and Tiffany…

LVMUY

LVMH

$0.00

(0.00%)

TIF

Tiffany

$123.32

-0.16 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$310.82

-1.07 (-0.34%)

17:51
11/20/19
11/20
17:51
11/20/19
17:51
Periodicals
Trump expected to sign bill supporting Hong Kong protesters, Bloomberg reports »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$310.82

-1.07 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRPX

Therapix Biosciences

$1.50

-0.13 (-7.98%)

17:49
11/20/19
11/20
17:49
11/20/19
17:49
Hot Stocks
Therapix Biosciences to appeal Nasdaq delisting notice »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LOW

Lowe's

$117.84

4.43 (3.91%)

17:47
11/20/19
11/20
17:47
11/20/19
17:47
Recommendations
Lowe's analyst commentary  »

Lowe's price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 03

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.